An MIT spinout, Synlogic, is aiming to create a new class of medicines, by re-programming bacteria found in the gut as “living therapeutics.” Based on research by its co-founders, MIT professors Tim Lu and Jim Collins, Synlogic creates so-called synthetic biotics, which sense and correct metabolic abnormalities that underlie some major diseases and rare genetic disorders. Human intestines are fill
![Reprogramming gut bacteria as “living therapeutics”](https://cdn-ak-scissors.b.st-hatena.com/image/square/d05bf788bdcdc2747e91014b5155e030d31c2b33/height=288;version=1;width=512/https%3A%2F%2Fnews.mit.edu%2Fsites%2Fdefault%2Ffiles%2Fimages%2F201604%2FMIT-Synlogic.jpg)